Red cell adhesion in human diseases

Current Opinion in Hematology

Volumn 21, Issue 3, 2014, Pages 186-192

  Colin, Yves ^a,b,c,d   Van Kim, Caroline Le ^a,b,c,d   El Nemer, Wassim ^a,b,c,d  

^a Institut National de la Transfusion Sanguine   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^d Laboratoire d'Excellence   (France)

Author keywords

adhesion; Lutheran basal cell adhesion molecule; red blood cells; vascular endothelium; vaso occlusion

Indexed keywords

BLOOD GROUP LUTHERAN SYSTEM; CELL ADHESION; CENTRAL RETINA VEIN OCCLUSION; ELLIPTOCYTOSIS; ERYTHROCYTE; GAUCHER DISEASE; HEREDITARY SPHEROCYTOSIS; HUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; THROMBOSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

CELL ADHESION; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; HUMANS; POLYCYTHEMIA VERA; SPHEROCYTOSIS, HEREDITARY;

EID: 84899489654     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000036     Document Type: Review

References (46)

1. Cartron JP, Elion J. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea. Transfus Clin Biol 2008; 15:39-50.
2. Grossin N, Wautier MP, Wautier JL. Red blood cell adhesion in diabetes mellitus is mediated by advanced glycation end product receptor and is modulated by nitric oxide. Biorheology 2009; 46:63-72.
3. Smith JD, Rowe JA, Higgins MK, Lavstsen T. Malaria's deadly grip: cytoadhesion of Plasmodium falciparum-infected erythrocytes. Cell Microbiol 2013; 15:1976-1983.
4. Connes P, Hue O, Tripette J, Hardy-Dessources MD. Blood rheology abnormalities and vascular cell adhesion mechanisms in sickle cell trait carriers during exercise. Clin Hemorheol Microcirc 2008; 39:179-184.
5. Kaul DK, Finnegan E, Barabino GA. Sickle red cell-endothelium interactions. Microcirculation 2009; 16:97-111.
6. Zennadi R, Hines PC, De Castro LM, et al. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood 2004; 104:3774-3781.
7. Zennadi R, Moeller BJ, Whalen EJ, et al. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood 2007; 110:2708-2717.
8. Bartolucci P, Chaar V, Picot J, et al. Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation. Blood 2010; 116:2152-2159.
9. El Nemer W, Gane P, Colin Y, et al. The Lutheran blood group glycoproteins, the erythroid receptors for laminin, are adhesion molecules. J Biol Chem 1998; 273:16686-16693.
10. Gauthier E, Rahuel C, Wautier MP, et al. Protein kinase A-dependent phosphorylation of Lutheran/basal cell adhesion molecule glycoprotein regulates cell adhesion to laminin alpha5. J Biol Chem 2005; 280:30055-30062.
11. Hines PC, Zen Q, Burney SN, et al. Novel epinephrine and cyclic AMPmediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood 2003; 101:3281-3287.
12. Udani M, Zen Q, Cottman M, et al. Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin. J Clin Invest 1998; 101:2550-2558.
13. Chaar V, Picot J, Renaud O, et al. Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease. Haematologica 2010; 95:1841-1848.
14. Zennadi R, Chien A, Xu K, et al. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 2008; 112:3474-3483.
15. Setty BN, Kulkarni S, Stuart MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood 2002; 99:1564-1571.
16. Kaul DK, Liu XD, Zhang X, et al. Peptides based on alphaV-binding domains of erythrocyte ICAM-4 inhibit sickle red cell-endothelial interactions and vaso-occlusion in the microcirculation. Am J Physiol Cell Physiol 2006; 291:C922-C930.
17. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood 1994; 83:553-560.
18. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 2000; 109:322-327.
19. Gallagher PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Semin Hematol 2004; 41:142-164.
20. Gallagher PG. Update on the clinical spectrum and genetics of red blood cell membrane disorders. Curr Hematol Rep 2004; 3:85-91.
21. An X, Mohandas N. Disorders of red cell membrane. Br J Haematol 2008; 141:367-375.
22. Wandersee NJ, Olson SC, Holzhauer SL, et al. Increased erythrocyte adhesion in mice and humans with hereditary spherocytosis and hereditary elliptocytosis. Blood 2004; 103:710-716.
23. Gauthier E, El Nemer W, Wautier MP, et al. Role of the interaction between Lu/BCAM and the spectrin-based membrane skeleton in the increased adhesion of hereditary spherocytosis red cells to laminin. Br J Haematol 2010; 148:456-465.
24. Sakamoto TM, Canalli AA, Traina F, et al. Altered red cell and platelet adhesion in hemolytic diseases: hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease. Clin Biochem 2013; 46:1798-1803.
25. Landolfi R, Marchioli R, Kati J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engle J Med 2004; 350:114-124.
26. Partial JT. Polycythemia vera and other primary polycythemias. Curr Opin Hematol 2005; 12:112-116.
27. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003; 102:3793-3796.
28. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-1061.
29. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144-1148.
30. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-1790.
31. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-397.
32. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64:1-12.
33. Andrews DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol 1999; 6:76-82.
34. Wautier MP, El Nemer W, Gane P, et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood 2007; 110:894-901.
35. De Grandis M, Cambot M, Wautier MP, et al. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoRindependent Rap1/Akt pathway. Blood 2013; 121:658-665.
36. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117:313-319; e311.
37. Cahill MT, Fekrat S. Arteriovenous sheathotomy for branch retinal vein occlusion. Ophthalmol Clin North Am 2002; 15:417-423.
38. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010; 8:1886-1894.
39. Janssen MC, den Heijer M, Cruysberg JR, et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93:1021-1026.
40. Heron E, Marzac C, Feldman-Billard S, et al. Endogenous erythroid colony formation in patients with retinal vein occlusion. Ophthalmology 2007; 114:2155-2161.
41. Wautier MP, Heron E, Picot J, et al. Red blood cell phosphatidylserine exposure is responsible for increased erythrocyte adhesion to endothelium in central retinal vein occlusion. J Thromb Haemost 2011; 9:1049-1055.
42. Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 1997; 10:657-689.
43. Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine 1985; 64:310-322.
44. Bratosin D, Tissier JP, Lapillonne H, et al. A cytometric study of the red blood cells in Gaucher disease reveals their abnormal shape that may be involved in increased erythrophagocytosis. Cytometry B Clin Cytom 2011; 80: 28-37.
45. Nilsson O, Hakansson G, Dreborg S, et al. Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III. Clin Genet 1982; 22:274-279.
46. Franco M, Collec E, Connes P, et al. Abnormal properties of red blood cells suggest a role in the pathophysiology of Gaucher disease. Blood 2013; 121:546-555.